

Risk of Cardiogenic Shock in Hypertrophic Cardiomyopathy

Colby Salerno, DO

Director, Hypertrophic Cardiomyopathy Program

Baystate Medical Center



Disclosures

- Speaker: Bristol Myers Squibb, Cytokinetics

Objectives


- 1. Identify patients with hypertrophic cardiomyopathy who are at increased risk for cardiogenic shock.
- 2. Discuss the pathophysiologic mechanisms contributing to hemodynamic collapse in hypertrophic cardiomyopathy.

Clinical Picture

- Two very different possible clinical shock scenarios
 - Mixed shock in the setting of oHCM
 - Cardiogenic shock due to end stage HCM

Mixed Shock

- oHCM
- LVOT obstruction – gradient
- Echo
- RHC
- Underlying driver
 - Sepsis, Anemia, Arrhythmia




Management

- Treat the underlying condition
- Beta blockers/ Calcium Channel Blockers
- Disopyromide
- Cardiac myosin inhibitors
- Septal Reduction Therapy

Cardiogenic Shock

- nHCM
- oHCM with or without ongoing obstruction
- Normal or Reduced EF



Presentation

- History
- NYHA class III-IV
- Vitals
- Volume Status

Management

- Inotropes
- Diuresis
- MCS?
- Advanced therapies

The End

- Questions?